[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_1040",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_1040"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB06650"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "chronic lymphocytic leukemia cll arzerra ofatumumab is indicated in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate see clinical studies 14 1 in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll see clinical studies 14 2 for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll see clinical studies 14 3 for the treatment of patients with cll refractory to fludarabine and alemtuzumab see clinical studies 14 4 arzerra ofatumumab is a cd2 directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia cll 1 in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll for the treatment of patients with cll refractory to fludarabine and alemtuzumab"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB06650",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-07-03T14:56:16.700+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "FKvGJ9o9bSfijSgwpIvb6s1Y90NuK6aE4jihBMEOzY+BJwpBcQB/9P7/ugJzvpKRmG0qSvfsSZ9+lSj7v4OY+Zgz2d+c3ZvBfOdUWwrR+DrWWdDA17qdqXGKyEheG/+vFTlWIe1ftC37KQsNBqymY1FKmRIOCXfXKeBE7YVhrdY="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#pubinfo"
} ]